Literature DB >> 18678667

Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14.

Dodi Safari1, Huberta A T Dekker, John A F Joosten, Dirk Michalik, Adriana Carvalho de Souza, Roberto Adamo, Martina Lahmann, Andreas Sundgren, Stefan Oscarson, Johannis P Kamerling, Harm Snippe.   

Abstract

Synthetic overlapping oligosaccharide fragments of Streptococcus pneumoniae serotype 14 capsular polysaccharide (Pn14PS), [6)-[beta-D-Galp-(1-->4)-]beta-D-GlcpNAc-(1-->3)-beta-D-Galp-(1-->4)-beta-D-Glcp-(1-->](n), were conjugated to CRM(197) protein and injected into mice to determine the smallest immunogenic structure. The resulting antibodies were then tested for Pn14PS specificity and for their capacity to promote the phagocytosis of S. pneumoniae type 14 bacteria. Earlier studies have reported that the oligosaccharide corresponding to one structural repeating unit of Pn14PS, i.e., Gal-Glc-(Gal-)GlcNAc, induces a specific antibody response to Pn14PS. The broader study described here, which evaluated 16 oligosaccharides, showed that the branched trisaccharide element Glc-(Gal-)GlcNAc is essential in inducing Pn14PS-specific antibodies and that the neighboring galactose unit at the nonreducing end contributes clearly to the immunogenicity of the epitope. Only the oligosaccharide conjugates that produce antibodies recognizing Pn14PS were capable of promoting the phagocytosis of S. pneumoniae type 14. In conclusion, the branched tetrasaccharide Gal-Glc-(Gal-)GlcNAc may be a serious candidate for a synthetic oligosaccharide conjugate vaccine against infections caused by S. pneumoniae type 14.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18678667      PMCID: PMC2546832          DOI: 10.1128/IAI.00472-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Streptococcus pneumoniae type 14 polysaccharide-conjugate vaccines: length stabilization of opsonophagocytic conformational polysaccharide epitopes.

Authors:  C A Laferriere; R K Sood; J M de Muys; F Michon; H J Jennings
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

2.  Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta.

Authors:  M A Breukels; G T Rijkers; M M Voorhorst-Ogink; B J Zegers; L A Sanders
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

3.  Length of the linker and the interval between immunizations influences the efficacy of Vibrio cholerae O1, Ogawa hexasaccharide neoglycoconjugates.

Authors:  Rina Saksena; Xingquan Ma; Terri K Wade; Pavol Kovác; William F Wade
Journal:  FEMS Immunol Med Microbiol       Date:  2006-06

4.  Antigenicity and immunogenicity of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b.

Authors:  V Fernández-Santana; Félix Cardoso; Arlene Rodriguez; Tania Carmenate; Luis Peña; Yuri Valdés; Eugenio Hardy; Fatme Mawas; Lazaro Heynngnezz; Maria C Rodríguez; Ignacio Figueroa; Janoi Chang; Maria E Toledo; Alexis Musacchio; Ibis Hernández; Mabel Izquierdo; Karelia Cosme; Rene Roy; V Verez-Bencomo
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

5.  Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.

Authors:  M B Rennels; K M Edwards; H L Keyserling; K S Reisinger; D A Hogerman; D V Madore; I Chang; P R Paradiso; F J Malinoski; A Kimura
Journal:  Pediatrics       Date:  1998-04       Impact factor: 7.124

6.  Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies.

Authors:  W T Jansen; J Gootjes; M Zelle; D V Madore; J Verhoef; H Snippe; A F Verheul
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

7.  Toward a carbohydrate-based HIV-1 vaccine: synthesis and immunological studies of oligomannose-containing glycoconjugates.

Authors:  Jiahong Ni; Haijing Song; Yadong Wang; Nicholas M Stamatos; Lai-Xi Wang
Journal:  Bioconjug Chem       Date:  2006 Mar-Apr       Impact factor: 4.774

8.  Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG.

Authors:  E Alonso de Velasco; A F Verheul; A M van Steijn; H A Dekker; R G Feldman; I M Fernández; J P Kamerling; J F Vliegenthart; J Verhoef; H Snippe
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

9.  Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.

Authors:  Roman Prymula; Pascal Peeters; Viktor Chrobok; Pavla Kriz; Elena Novakova; Eva Kaliskova; Igor Kohl; Patricia Lommel; Jan Poolman; Jean-Paul Prieels; Lode Schuerman
Journal:  Lancet       Date:  2006-03-04       Impact factor: 79.321

Review 10.  Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines.

Authors:  E AlonsoDeVelasco; A F Verheul; J Verhoef; H Snippe
Journal:  Microbiol Rev       Date:  1995-12
View more
  33 in total

1.  A peptide-free, liposome-based oligosaccharide vaccine, adjuvanted with a natural killer T cell antigen, generates robust antibody responses in vivo.

Authors:  S Deng; L Bai; R Reboulet; R Matthew; D A Engler; L Teyton; A Bendelac; P B Savage
Journal:  Chem Sci       Date:  2014-04       Impact factor: 9.825

2.  Natural killer T (NKT)-B-cell interactions promote prolonged antibody responses and long-term memory to pneumococcal capsular polysaccharides.

Authors:  Li Bai; Shenglou Deng; Rachel Reboulet; Rebecca Mathew; Luc Teyton; Paul B Savage; Albert Bendelac
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

3.  A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.

Authors:  Sharavathi Guddehalli Parameswarappa; Katrin Reppe; Andreas Geissner; Petra Ménová; Subramanian Govindan; Adam D J Calow; Annette Wahlbrink; Markus W Weishaupt; Bopanna Ponnappa Monnanda; Roland Lawrence Bell; Liise-Anne Pirofski; Norbert Suttorp; Leif Erik Sander; Martin Witzenrath; Claney Lebev Pereira; Chakkumkal Anish; Peter H Seeberger
Journal:  Cell Chem Biol       Date:  2016-11-03       Impact factor: 8.116

4.  Conjugate Vaccines from Bacterial Antigens by Squaric Acid Chemistry: A Closer Look.

Authors:  Peng Xu; Meagan Kelly; Willie F Vann; Firdausi Qadri; Edward T Ryan; Pavol Kováč
Journal:  Chembiochem       Date:  2017-03-23       Impact factor: 3.164

5.  Preparation, characterization and immunogenicity of HIV-1 related high-mannose oligosaccharides-CRM197 glycoconjugates.

Authors:  Anna Kabanova; Roberto Adamo; Daniela Proietti; Francesco Berti; Marta Tontini; Rino Rappuoli; Paolo Costantino
Journal:  Glycoconj J       Date:  2010-06-04       Impact factor: 2.916

6.  The immune response to group B streptococcus type III capsular polysaccharide is directed to the -Glc-GlcNAc-Gal- backbone epitope.

Authors:  Dodi Safari; Huberta A T Dekker; Ger T Rijkers; Arie van der Ende; Johannis P Kamerling; Harm Snippe
Journal:  Glycoconj J       Date:  2011-10-08       Impact factor: 2.916

7.  A semisynthetic Streptococcus pneumoniae serotype 8 glycoconjugate vaccine.

Authors:  Benjamin Schumann; Heung Sik Hahm; Sharavathi G Parameswarappa; Katrin Reppe; Annette Wahlbrink; Subramanian Govindan; Paulina Kaplonek; Liise-Anne Pirofski; Martin Witzenrath; Chakkumkal Anish; Claney L Pereira; Peter H Seeberger
Journal:  Sci Transl Med       Date:  2017-03-08       Impact factor: 17.956

8.  Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge.

Authors:  Manuel Osorio; Yanping Wu; Sunil Singh; Tod J Merkel; Siba Bhattacharyya; Milan S Blake; Dennis J Kopecko
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

9.  Chemical synthesis of the outer core oligosaccharide of Escherichia coli R3 and immunological evaluation.

Authors:  Wenjing Shang; Zhongying Xiao; Zaikuan Yu; Na Wei; Guohui Zhao; Qing Zhang; Mohui Wei; Xuan Wang; Peng George Wang; Tiehai Li
Journal:  Org Biomol Chem       Date:  2015-03-12       Impact factor: 3.876

10.  Structure of a protective epitope of group B Streptococcus type III capsular polysaccharide.

Authors:  Filippo Carboni; Roberto Adamo; Monica Fabbrini; Riccardo De Ricco; Vittorio Cattaneo; Barbara Brogioni; Daniele Veggi; Vittoria Pinto; Irene Passalacqua; Davide Oldrini; Rino Rappuoli; Enrico Malito; Immaculada Y Ros Margarit; Francesco Berti
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.